Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Avidity Biosciences Inc (NQ: RNA ) 46.72 -0.79 (-1.66%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Avidity Biosciences Inc < Previous 1 2 3 4 5 6 Next > In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences October 21, 2024 Via Benzinga Evaluating Avidity Biosciences: Insights From 10 Financial Analysts October 21, 2024 Via Benzinga Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up October 18, 2024 The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. Via Investor's Business Daily 12 Health Care Stocks Moving In Monday's After-Market Session October 07, 2024 Via Benzinga Why Avidity Biosciences Zoomed to a 12% Gain This Week October 04, 2024 The company's most promising pipeline program can continue unabated. Via The Motley Fool Unveiling 7 Analyst Insights On Avidity Biosciences September 16, 2024 Via Benzinga Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings) August 28, 2024 Via Benzinga The Analyst Landscape: 7 Takes On Avidity Biosciences August 12, 2024 Via Benzinga (RNA) - Analyzing Avidity Biosciences's Short Interest June 20, 2024 Via Benzinga Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases September 24, 2024 Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular... Via Benzinga Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease September 09, 2024 BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... Via Benzinga RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024 August 09, 2024 RNA stock results show that Avidity Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday August 09, 2024 Via Benzinga Chart Of The Day: Avidity Biosciences - Something's Up? June 14, 2024 Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. Via Talk Markets How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics August 09, 2024 The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. Via Investor's Business Daily 3 Stocks Doing Even Better Than Superstar Super Micro (SMCI) July 24, 2024 These three stellar, outperforming stocks are doing better than even Super Micro Computer, which has been running away from the market. Via InvestorPlace 3 Russell 2000 Growth Stocks That Could Be Worth the Risk July 23, 2024 These three small-cap stocks could deliver hefty returns if the central bank cuts rates. Via The Motley Fool Topics Economy Exposures Interest Rates GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing July 18, 2024 GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. Via Benzinga Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows July 01, 2024 June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. Via Benzinga Topics ETFs Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... Via Talk Markets Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio? June 16, 2024 Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry. Via Benzinga Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday June 14, 2024 Via Benzinga Crude Oil Moves Higher; Vera Bradley Shares Slide June 12, 2024 Via Benzinga Exposures Fossil Fuels Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session June 12, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session June 12, 2024 Via Benzinga Nasdaq Jumps 300 Points; Oracle Shares Spike Higher June 12, 2024 Via Benzinga Why Avidity Biosciences Shares Are Trading Higher Wednesday June 12, 2024 The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran. Via Benzinga Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday June 12, 2024 Via Benzinga The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A High Point June 12, 2024 The company is working on a treatment for a rare form of muscular dystrophy. Via Investor's Business Daily 12 Health Care Stocks Moving In Wednesday's Pre-Market Session June 12, 2024 Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
